Dr. Mark Ilgen, Ph.D.
Claim this profileUniversity of Michigan
Studies Brain-Derived Neurotrophic Factor
Studies Suicide
4 reported clinical trials
7 drugs studied
Affiliated Hospitals
Clinical Trials Mark Ilgen, Ph.D. is currently running
Crisis Line Support
for Suicide Prevention in Alcoholism
The purpose of this research study is to learn about people who use the National Suicide Prevention (NSP) Lifeline during a suicidal crisis and those who don't. The researchers would also like to learn whether people who have experienced a suicidal crisis could benefit from participating in a therapy session about their thoughts and perceptions of the NSP Lifeline.
Recruiting1 award N/A2 criteria
ACT + Mindfulness
for Chronic Pain & Opioid Use Disorder
This study is a multisite randomized clinical trial of a treatment designed to reduce pain interference while simultaneously addressing relapse prevention among individuals who have co-occurring chronic pain and Opioid Use Disorder (OUD). This study will recruit approximately 160 individuals who are currently being treated in clinics specializing in the physician management of OUD. To increase generalizability of study findings and increase internal validity of the physician management component of treatment, all participants will be stabilized on buprenorphine for OUD as part of their usual clinical care. Individuals will be randomized to either: (1) enhanced usual care or (2) the integrated ACT + MBRP treatment. The investigators hypothesize that: (1) the combination of ACT + MBRP in buprenorphine-prescribed patients with chronic pain will be more efficacious across primary and secondary outcome measures in comparison to Enhanced Usual Care and (2) examination of treatment mechanism data will indicate treatment-related changes that are consistent with the theoretical models of ACT+MBRP.
Recruiting1 award N/A
More about Mark Ilgen, Ph.D.
Clinical Trial Related4 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Mark Ilgen, Ph.D. has experience with
- Crisis Line Facilitation (CLF)
- Enhanced Usual Care (EUC)
- Passive Implementation
- Acceptance And Commitment Therapy + Mindfulness Based Relapse Prevention (ACT + MBRP)
- Enhance Usual Care (EUC)
- Enhanced Usual Care
Breakdown of trials Mark Ilgen, Ph.D. has run
Brain-Derived Neurotrophic Factor
Suicide
Opioid Use Disorder
Chronic Pain
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mark Ilgen, Ph.D. specialize in?
Mark Ilgen, Ph.D. focuses on Brain-Derived Neurotrophic Factor and Suicide. In particular, much of their work with Brain-Derived Neurotrophic Factor has involved treating patients, or patients who are undergoing treatment.
Is Mark Ilgen, Ph.D. currently recruiting for clinical trials?
Yes, Mark Ilgen, Ph.D. is currently recruiting for 2 clinical trials in Ann Arbor Michigan. If you're interested in participating, you should apply.
Are there any treatments that Mark Ilgen, Ph.D. has studied deeply?
Yes, Mark Ilgen, Ph.D. has studied treatments such as Crisis Line Facilitation (CLF), Enhanced Usual Care (EUC), Passive Implementation.
What is the best way to schedule an appointment with Mark Ilgen, Ph.D.?
Apply for one of the trials that Mark Ilgen, Ph.D. is conducting.
What is the office address of Mark Ilgen, Ph.D.?
The office of Mark Ilgen, Ph.D. is located at: University of Michigan, Ann Arbor, Michigan 48105 United States. This is the address for their practice at the University of Michigan.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.